Skip to Navigation Skip to Search Skip to Content
Search All Centers

Can Tests Reveal a CLL Patient’s Potential for Developing Treatment Resistance?

Read Transcript Download/Print Transcript

Published on March 20, 2019

Patient Power community member Theresa writes in, “Although my husband is doing well, is there testing to know whether he will develop treatment resistance in the future?” During this Ask the Expert segment, renowned chronic lymphocytic leukemia (CLL) expert Dr. Richard Furman, from Weill Cornell Medicine, responds by sharing research on CLL patients with mutations and clinical relapse. Watch now to learn more.

This is a Patient Empowerment Network program produced by Patient Power. We thank AbbVie, Inc. and Pharmacyclics for their support.

Featuring

Sponsors

Patient Empowerment Network

You might also like

Transcript | Can Tests Reveal a CLL Patient’s Potential for Developing Treatment Resistance?

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.

And, two, is you really—you know, in essence when you look at the data that suggests that 92 percent of patients who get ibrutinib (Imbruvica) as a first-line therapy will remain in remission at five years you're talking about treating--or testing a lot of people for very, very few people that will likely benefit.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.